USA Today: Massive marketing investments—not clinical evidence—buying 3D mammography acceptance
U.S. mammography centers have strongly embraced 3D mammography (digital breast tomosynthesis)—although its value has not been demonstrated in large-scale clinical trials.
That’s the conclusion of an investigation conducted by Kaiser Health News and published in USA Today on Oct. 18. The investigation revealed that mammography vendors, hospitals, physicians and patient advocates have invested millions of dollars in pushing 3D mammograms, “despite no evidence that they save more lives.” This, the newspaper reports, “has left many women feeling pressured to undergo screenings, which according to the U.S. Preventive Services Task Force (USPSTF), have not been demonstrated to be more effective than traditional mammograms.”
USA Today’s coverage delved into four means through which industry money has, if the investigation is any indication, “shaped policy, public opinion, and patient care” in 3D mammography’s favor. These include payments to influential physicians, direct marketing to consumers, lobbying of state lawmakers, and funding of initiatives by experts and advocates.
The coverage also features commentary from proponents of 3D mammography, along with opposing viewpoints from its detractors.
Find out more by clicking the link below: